Online inquiry

IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11346MR)

This product GTTS-WQ11346MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11346MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7265MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ1892MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ10792MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ15260MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ14165MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ9176MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ8706MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ4374MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-188667
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW